| Bioactivity | Triheptanoin (Propane-1,2,3-triyl triheptanoate) is a synthetic medium-chain triglyceride (MCT) consisting of three odd-chain 7-carbon (heptanoate) fatty acids on a glycerol backbone. Triheptanoin can be used for the research of inherited metabolic disorders[1]. |
| In Vivo | In long-chain fatty acid oxidation disorders (LC-FAOD), Triheptanoin is used as an anaplerotic compound, acting as a source of calories and fatty acids to bypass the LC-FAOD enzyme deficiencies[1].Triheptanoin can be used for the research of ataxia-telangiectasia (A-T)[2].Triheptanoin functions as an anaplerotic agent replenishing tricarboxylic acid (TCA) cycle intermediates by metabolism to heptanoate (C7) and subsequently acetyl-CoA and propionyl-CoA that feed into the TCA cycle to supply energy[2]. Triheptanoin mitigates brain ATP depletion and mitochondrial dysfunction, including respiration and redox balance in a mouse model of Alzheimer's disease, supporting the energy failure hypothesis for that disorder[2].Triheptanoin (Mice were treated with Triheptanoin (35E%) for 10 days prior to pilocarpine injection to induce status epilepticus) preserved mitochondrial functions in the hippocampal formations of pilocarpine-induced status epilepticus (SE) mice[3]. Animal Model: |
| Name | Triheptanoin |
| CAS | 620-67-7 |
| Formula | C24H44O6 |
| Molar Mass | 428.61 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Matt Shirley. Triheptanoin: First Approval. Drugs. 2020 Oct;80(15):1595-1600. [2]. A J Yeo, et al. An anaplerotic approach to correct the mitochondrial dysfunction in ataxia-telangiectasia (A-T). Mol Metab. 2021 Dec;54:101354. [3]. Kah Ni Tan, et al. Triheptanoin protects against status epilepticus-induced hippocampal mitochondrial dysfunctions, oxidative stress and neuronal degeneration. J Neurochem. 2018 Feb;144(4):431-442. |